A phase 3 study of Bardoxolone Methyl 1 (RTA 402) to treat patients with Diabetic Kidney Disease-2 (DKD).
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Diabetic neuropathies
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 04 Apr 2018 New trial record
- 28 Mar 2018 According to a Kyowa Hakko Kirin media release, company plans to initiate this study in 2018 in Japan.